Quilizumab, a humanized afucosalyted IgG1 monoclonal antibody, directed against the M1 prime segment of membrane-expressed IgE (mIgE), down-regulated serum IgE levels without sufficient clinical effects in patients with inadequately controlled asthma [184] or chronic spontaneous urticaria [185]. This evidence concerns the gene IGHE and asthma.